Pembrolizumab (Trade name Keytruda®) is a human monoclonal antibody used to block the action of Programmed Cell Death Protein 1(PD-1). Upregulation of PD-1 ligands on tumor cells can allow the tumor to evade anti-tumor immune response. By blocking PDL1 and PD-L2 binding to PD-1, Pembrolizumab induces an anti-tumor immune response by allowing full activation of the anti-tumor T cell response. Thus, Pembrolizumab acts as a checkpoint inhibitor to stimulate immune responses to eliminate cancer cells.
The Pembrolizumab ELISA kit is designed to measure free Pembrolizumab with high specificity and sensitivity. The assay design uses a pair of antibodies allowing detection of whole Pembrolizumab molecules in biological matrices.
PRINCIPLE OF THE ASSAY
This assay employs the sandwich enzyme immunoassay technique. Standards and test samples are pipetted into the appropriate wells. Pembrolizumab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, enzyme linked detection antibody is added to the wells. The plate is washed to remove any unbound antibody enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Pembrolizumab present in test samples.